HOPO Chelator,cas110874-36-7

(Chelating agent for Gadolinium,Radioactive elements,Zirconium-89)

Use:
1. therapeutic metal chelating agent for Environmental contaminants like lead and cadmium
2. therapeutic metal chelating agent for Gadolinium that deposits in the body after exposure to MRI contrast agents
3. therapeutic metal chelating agent for Radioactive elements such as Plutonium, Americium, Uranium，and other actinides
4. Spermine-based hydroxypyridonate octadentate chelator 3,4,3-LI(1,2-HOPO) has great potential as a therapeutic metal chelating agent.
5. Ultimate Chelator HOPO for Zirconium-89 (89Zr) based PET imaging agents.

MF：C34H38N8O12
MW：750.71

Synonyms:
HOPO,KUN74367,KUN-74367,N,N'-1,4-Butanediylbis(N-(3-(((1,6-dihydro-1-hydroxy-6-oxo-2-pyridinyl)carbonyl)amino)propyl)-1,6-dihydro-1-hydroxy-6-oxo-2- pyridinecarboxamide,hydroxypyridonate,LiHOPO,treatment of Gadolinium Poisoning,Gd Poisoning,Gadolinium chelating agent,Gadolinium Chelator,hopo chelator drug for Uranium (U),hopo chelator drug for Gadolinium (Gd),3 4 3-LI(1 2-HOPO) to reduce Uranium (U),3 4 3-LI(1 2-HOPO) to reduce Plutonium (Pu),3 4 3-LI(1 2-HOPO) to reduce Americium (Am),hopo chelator drug for Plutonium (Pu),hopo chelator drug for Americium (Am),Chelator for Environmental contaminants like lead and cadmium,therapeutic metal chelating agent for Environmental contaminants like lead and cadmium,therapeutic metal chelating agent for Gadolinium,therapeutic metal chelating agent for Gadolinium,Chelator for Radioactive elements plutonium,Chelator for Radioactive elements americium,Chelator for Radioactive elements other actinides,therapeutic metal chelating agent for Radioactive elements plutonium, therapeutic metal chelating agent for Radioactive elements americium,therapeutic metal chelating agent for Radioactive elements other actinides,HOPO Chelator-removal of Gd based contrast agents,HOPO Chelator-removal of gadolinium-based contrast,HOPO Chelator -How to remove gadolinium from the body,HOPO Chelator -detox gadolinium,HOPO Chelator -gadolinium detox,HOPO Chelator -Gd detox,HOPO Chelator -Remove Gadolinium From Brain And Body Tissue,HOPO Chelator-Treatment Possibilities for Gadolinium Toxicity,HOPO Chelator-how to chelate gadolinium,HOPO Chelator-how to prevent gadolinium toxicity,HOPO Chelator-gadolinium toxicity treatment,HOPO Chelator-who treats gadolinium poisoning,HOPO Chelator-how to remove gadolinium from the brain,HOPO Chelator-how to get gadolinium out of your system,HOPO Chelator-how to remove gadolinium from the body,buy HOPO Chelator,hopo chelator detox Cadmium,hopo chelator detox Lead,hopo chelator detox gadolinium,hopo chelator detox Plutonium,hopo chelator detox Americium,hopo chelator detox Uranium,hopo chelator detox actinides,hopo chelator detox Radioactive elements,HOPO Chelator buy,Gadolinium Retention,Zirconium-89 Chelator HOPO,hopo chelator for Gadolinium-based contrast agents toxicity,hopo chelator to cure Gadolinium-based contrast agents poisoning,HOPO chelation for gadolinium,Gadolinium toxicity treatment by HOPO Chelator,HOPO Chelator for Gadolinium (Gd),HOPO Chelator treats gadolinium poisoning,HOPO Chelating agent for gadolinium,Gadolinium deposition disease treatment by HOPO Chelator,Gadolinium chelation therapy with HOPO Chelator,3 4 3-li(1 2-hopo) gadolinium,3 4 3-li(1 2-hopo) americium,3 4 3-li(1 2-hopo) plutonium,3 4 3-li(1 2-hopo) Radioactive elements,3 4 3-li(1 2-hopo) Uranium,3 4 3-li(1 2-hopo) actinides,3 4 3-li(1 2-hopo) Lead,3 4 3-li(1 2-hopo) Cadmium,HOPO Chelator FandaChem,hopo chelator detox gadolinium,HOPO chelator FandaChem,
110874-36-7 FandaChem,3 4 3-Li(1 2-HOPO) FandaChem,

Properties：
Appearance: Solid powder
Solubility: Soluble in DMSO
Drug Formulation: This drug may be formulated in DMSO
Purity:  95%+;   98%+

Introduction
HOPO Chelator (3,4,3-Li(1,2-HOPO),CAS 110874-36-7) is a very efficient ligand to remove actinides from the body after simulated contamination.and It has been
evaluated for potential biomedical applications; thus, toxicology and pharmacology studies have already been completed. In addition,
the in vivo stability of metal complexes of 3,4,3-Li(1,2-HOPO)formed with both trivalent (Eu, Am, Cm) and tetravalent (Zr, Pu)
metals has been investigated in multiple studies, using ex vivo radioanalytical techniques and in vivo PET imaging.

Probably HOPO Chelator (3,4,3-Li(1,2-HOPO),CAS 110874-36-7) become a therapeutic chelating agent for gadolinium, which is used in MRI contrast agents. (chelation therapy in patients exposed to gadolinium-based contrast agents)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks
during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0-4℃ for short term (days to weeks) or -20℃ for long term (months to years).
Shelf Life: >3 years if stored properly
HS Tariff Code: 2934.99.9001

Experiment and Practice
3,4,3-Li(1,2-HOPO) CAS No.: 110874-36-7 is known to have high affinity for both trivalent and tetravalent lanthanide and actinide cations. Here we extend its coordination chemistry to the rare-earth cations Sc3? and Y3? and characterize fundamental metal-chelator binding interactions in solution via UV-Vis spectrophotometry, nuclear magnetic resonance spectroscopy, and spectrofluorimetric metal-competition titrations, as well as in the solid-state via single crystal X-ray diffraction. Sc3? and Y3? binding with3,4,3-Li(1,2-HOPO) CAS No.: 110874-36-7 is found to be robust, with both high thermodynamic stability and fast room temperature radiolabeling, indicating that 3,4,3-Li(1,2-HOPO) CAS No.: 110874-36-7 is likely a promising chelator for in vivo applications with both metals. So the potential of 343-HOPO chelated trivalent metal cations for therapeutic and theranostic applications.

Siderophore-inspired multidentate hydroxypyridonate ligands can be used in a variety of applications such as magnetic resonance imaging (MRI) contrast enhancement, lanthanide luminescence sensitization, and iron and actinide chelation.The octadentate ligand 3,4,3-LI(1,2-HOPO), composed of four 1-hydroxy-pyridin-2-one (1,2-HOPO) units linked to a spermine scaffold through amide linkages, is currently considered the most efficient experimental decorporation agent for actinides.Studies have shown that this ligand is orally active and is by far more efficacious than the commonly used diethylenetriamine-pentaacetic acid at promoting the in vivo decorporation of actinide metal ions, such as UVI, NpV, PuIV, and AmIII.In addition, 3,4,3-LI(1,2-HOPO) is known to act as an antenna that sensitizes the luminescence of EuIII, a feature that was used recently to determine the solution thermodynamic stability of the corresponding [EuIII(3,4,3-LI(1,2-HOPO))]? complex. In the work presented here, the photophysical properties of the complexes of 3,4,3-LI(1,2-HOPO) formed with metal ions from the whole lanthanide series were probed and characteristic emission sensitization was observed in both the Visible and Near Infra-Red ranges, depending on the complexed metal ion. The use of the antenna effect as a spectroscopic tool was extended to spectrofluorimetric competition titrations, to determine the formation constants of these lanthanide complexes. While such thermodynamic parameters are essential to characterize 3,4,3-LI(1,2-HOPO) as a chelating agent and compare its affinity to different metal ions, they are only indicative of the potential in vivo decorporation efficacy of the
ligand. The in vivo EuIII complex stability and EuIII decorporation capacity of 3,4,3-LI(1,2-HOPO) were therefore also assessed in mice, using the radioactive isotope 152Eu as a contaminant, which provides a direct comparison with the in vitro thermodynamic results.

The high affinity of this chelator for lanthanides, as compared to DTPA, indicates its potential as a therapeutic chelating agent for f-block metal ions, which was confirmed through the first in vivo decorporation and stability experiments using the radiotracer 152Eu, a common fission product in the nuclear fuel process. Other radionuclides potentially targeted by HOPO Chelator (3,4,3-Li(1,2-HOPO),CAS 110874-36-7) include tri- and tetravalent actinides such as Pu(IV) and Am(III). The analytical methods used here will be applied to the determination of the photophysical properties and thermodynamic parameters of the corresponding 3,4,3-LI(1,2-HOPO) complexes, providing a rationale to the use and design of new decorporation agents. In addition, sensing f-block metal ions through luminescence spectroscopy has the potential to ease and significantly improve current actinide detection and characterization methods in terms of selectivity and accuracy.

How do you get rid of gadolinium naturally?
Use HOPO Chelator.

Can you chelate gadolinium?
Yes, HOPO Chelator is most advanced and highly selective Chelator.

What is used to chelate gadolinium?
HOPO Chelator (3,4,3-Li(1,2-HOPO) CAS No.: 110874-36-7)

How do you get gadolinium toxicity?
For any patients exposed to gadolinium-based contrast agents will get Gadolinium toxicity.

how to chelate gadolinium ?
Use HOPO Chelator (3,4,3-Li(1,2-HOPO) CAS No.: 110874-36-7)

how to flush out mri contrast dye?
Use HOPO Chelator (3,4,3-Li(1,2-HOPO) CAS No.: 110874-36-7)

how to flush kidneys after mri?
Use HOPO Chelator (3,4,3-Li(1,2-HOPO) CAS No.: 110874-36-7).

dtpa chelation for gadolinium ?
it is not good one, in fact very bad.
HOPO Chelator is most advanced and highly selective Chelator.

What is HOPO Chelator? What does it do?
HOPO Chelator is 3,4,3-Li(1,2-HOPO) CAS No.: 110874-36-7, a highly selective heavy metal chelator.
It is specifically designed to selectively bind lead, cadmium, ,Gadolinium , Radioactive elements such as plutonium, americium, and other actinides, Zirconium-89 (89Zr) based PET imaging agents and promote their removal from the body, without chelating essential metals like iron, calcium, and zinc.

What kinds of metals does HOPO Chelator chelates?
a wide range of heavy metals including lead, cadmium, and tin, as well most lanthanide and actinide elements like gadolinium, and the radioactive elements uranium, plutonium, and americium, Zirconium-89 (89Zr) based PET imaging agents.

Can HOPO Chelator help children and communities impacted by lead or other heavy metal poisoning?
Yes for Lead Poisoning in Children.

Can HOPO Chelator remove gadolinium deposited from MRI contrast agents?
Yes. HOPO Chelator has been proven far more effective than DTPA to remove gadolinium from the body in preclinical studies.

Does HOPO Chelator cross the blood-brain barrier?
Yes. The preclinical pharmacokinetics and biodistribution of HOPO Chelator have been studied.

Will HOPO Chelator chelate deposited gadolinium that is “free” AND gadolinium still bound to a GBCA chelator?
Based on the available data, yes, however now it is insufficient evidence.

Can I purchase or obtain HOPO Chelator?
At the moment, unfortunately no.
Please follow two companies: HOPO Therapeutics, Inc. and FandaChem.

Can you answer questions or provide medical advice about metal toxicity or chelation treatments?
No, should do Medical test.

What can I do to stay informed about your progress?
Pls visit website and then contact by whatsapp or Email.

When will you be starting clinical trials?
Our lead drug candidate, an oral formulation of 3,4,3-LI(1,2-HOPO), has been granted Investigational New Drug status by the FDA, meaning it has been shown to be both safe and effective in preclinical studies. We have cleared all of the regulatory milestones necessary to begin clinical trials, and we are seeking funding for them. We anticipate conducting clinical trials - once it is safe to do so - to assess both safety and pharmacokinetics, as well as efficacy for chelation of gadolinium.

Can I sign up to participate in a clinical trial?
No.

What is used to chelate gadolinium?
HOPO Chelator (3,4,3-Li(1,2-HOPO) CAS No.: 110874-36-7).

What are Group 2 gadolinium agents?
HOPO Chelator (3,4,3-Li(1,2-HOPO) CAS No.: 110874-36-7)

What is the safest MRI contrast agent?
HOPO Chelator (3,4,3-Li(1,2-HOPO) CAS No.: 110874-36-7)

Why is gadolinium chelation important?
Pls check the Gadolinium toxicity and Gadolinium side effects.

References
1. P. W. Durbin, Health Phys., 2008, 95, 465-492.
2. K. Djanashvili and J. A. Peters, Contrast Media Mol. Imaging, 2007, 2, 67-71.
3. E. G. Moore, A. P. S. Samuel, and K. N. Raymond, Acc. Chem. Res., 2009, 42, 542-552.
4. R. C. Scarrow, P. E. Riley, K. Abu-Dari, D. L. White, and K. N. Raymond, Inorg. Chem., 1985, 24, 954-967.
5. E. J. Werner, A. Datta, C. J. Jocher, and K. N. Raymond, Angew. Chem. Int. Ed., 2008, 47, 8568-8580.
6. R. J. Abergel, P. W. Durbin, B. Kullgren, S. N. Ebbe, J. Xu, P. Y. Chang, D. I. Bunin, E. A. Blakely, K. A. Bjornstad, C. J.
Rosen, D. K. Shuh, and K.
E. G. Moore, C. J. Jocher, J. Xu, E. J. Werner, and K. N. Raymond, Inorg. Chem., 2007, 46, 5468-5470.
N. Raymond, Health Phys., 2010, 99, 401-407.
7. P. W. Durbin, B. Kullgren, S. N. Ebbe, J. Xu, and K. N. Raymond, Health Phys., 2000, 78, 511.
8. R. J. Abergel and K. N. Raymond, Hemoglobin, 2011, 35.
9. R. J. Abergel, A. D’Aleo, C. Ng Pak Leung, D. K. Shuh, and K. N. Raymond, Inorg. Chem., 2009, 48, 10868-10870.
10. P. Gans and B. O’Sullivan, Talanta, 2000, 51, 33-37.
11. A. Heller, A. Barkleit, and G. Bernhard, Chem. Res. Toxicol., 2011, 24, 193-203.
12. P. Gans, A. Sabatini, and A. Vacca, HYPERQUAD2000, Leeds, U.K. Florence, Italy.
13. P. Gans, A. Sabatini, and A. Vacca, Talanta, 1996, 43, 1739-1753.
14. P. Gans, A. Sabatini, and A. Vacca, Ann. Chim., 1999, 89, 45-49.
15. P. Gans, A. Sabatini, and A. Vacca, HypSpec, Leeds, U.K. Florence, Italy.